Report cover image

Global Biomolecule Software Market Analysis and Forecast 2026-2032

Publisher APO Research, Inc.
Published Jan 01, 2026
Length 212 Pages
SKU # APRC20796875

Description

The global Biomolecule Software market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Biomolecule Software is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Biomolecule Software is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Asia-Pacific market for Biomolecule Software is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Biomolecule Software is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Biomolecule Software include Hamilton Thorne, Hermes Medical Solutions, Inc, INDICAL BIOSCIENCE, lexogen, Repligen, SCC SOFT COMPUTER, Oxford Instruments, Partek, Inc. and Stilla Technologies, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Biomolecule Software, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Biomolecule Software, also provides the revenue of main regions and countries. Of the upcoming market potential for Biomolecule Software, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Biomolecule Software revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Biomolecule Software market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Biomolecule Software revenue, projected growth trends, production technology, application and end-user industry.

Biomolecule Software Segment by Company

Hamilton Thorne
Hermes Medical Solutions, Inc
INDICAL BIOSCIENCE
lexogen
Repligen
SCC SOFT COMPUTER
Oxford Instruments
Partek, Inc.
Stilla Technologies
Vela Diagnostics
Vittoriobasurto
SCIEX
SoftGenetics, LLC.
Benchling
BioSistemika
CapitalBio Technology
cytena GmbH
Eppendorf SE
GenomSys
Mission Bio
Multid Analyses AB
PhenoSystems SA
Progenie Molecular

Biomolecule Software Segment by Type

Windows
Linux
MacOS

Biomolecule Software Segment by Application

Hospital
Clinic
Research Center

Biomolecule Software Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biomolecule Software market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biomolecule Software and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biomolecule Software.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Biomolecule Software in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Biomolecule Software company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Biomolecule Software revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.

Table of Contents

212 Pages
1 Market Overview
1.1 Product Definition
1.2 Biomolecule Software Market by Type
1.2.1 Global Biomolecule Software Market Size by Type, 2021 VS 2025 VS 2032
1.2.2 Windows
1.2.3 Linux
1.2.4 MacOS
1.3 Biomolecule Software Market by Application
1.3.1 Global Biomolecule Software Market Size by Application, 2021 VS 2025 VS 2032
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Research Center
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Biomolecule Software Market Dynamics
2.1 Biomolecule Software Industry Trends
2.2 Biomolecule Software Industry Drivers
2.3 Biomolecule Software Industry Opportunities and Challenges
2.4 Biomolecule Software Industry Restraints
3 Global Growth Perspective
3.1 Global Biomolecule Software Market Perspective (2021-2032)
3.2 Global Biomolecule Software Growth Trends by Region
3.2.1 Global Biomolecule Software Market Size by Region: 2021 VS 2025 VS 2032
3.2.2 Global Biomolecule Software Market Size by Region (2021-2026)
3.2.3 Global Biomolecule Software Market Size by Region (2027-2032)
4 Competitive Landscape by Players
4.1 Global Biomolecule Software Revenue by Players
4.1.1 Global Biomolecule Software Revenue by Players (2021-2026)
4.1.2 Global Biomolecule Software Revenue Market Share by Players (2021-2026)
4.1.3 Global Biomolecule Software Players Revenue Share Top 10 and Top 5 in 2025
4.2 Global Biomolecule Software Key Players Ranking, 2024 VS 2025 VS 2026
4.3 Global Biomolecule Software Key Players Headquarters & Area Served
4.4 Global Biomolecule Software Players, Product Type & Application
4.5 Global Biomolecule Software Players Establishment Date
4.6 Market Competitive Analysis
4.6.1 Global Biomolecule Software Market CR5 and HHI
4.6.3 2025 Biomolecule Software Tier 1, Tier 2, and Tier 3
5 Biomolecule Software Market Size by Type
5.1 Global Biomolecule Software Revenue by Type (2021 VS 2025 VS 2032)
5.2 Global Biomolecule Software Revenue by Type (2021-2032)
5.3 Global Biomolecule Software Revenue Market Share by Type (2021-2032)
6 Biomolecule Software Market Size by Application
6.1 Global Biomolecule Software Revenue by Application (2021 VS 2025 VS 2032)
6.2 Global Biomolecule Software Revenue by Application (2021-2032)
6.3 Global Biomolecule Software Revenue Market Share by Application (2021-2032)
7 Company Profiles
7.1 Hamilton Thorne
7.1.1 Hamilton Thorne Company Information
7.1.2 Hamilton Thorne Business Overview
7.1.3 Hamilton Thorne Biomolecule Software Revenue and Gross Margin (2021-2026)
7.1.4 Hamilton Thorne Biomolecule Software Product Portfolio
7.1.5 Hamilton Thorne Recent Developments
7.2 Hermes Medical Solutions, Inc
7.2.1 Hermes Medical Solutions, Inc Company Information
7.2.2 Hermes Medical Solutions, Inc Business Overview
7.2.3 Hermes Medical Solutions, Inc Biomolecule Software Revenue and Gross Margin (2021-2026)
7.2.4 Hermes Medical Solutions, Inc Biomolecule Software Product Portfolio
7.2.5 Hermes Medical Solutions, Inc Recent Developments
7.3 INDICAL BIOSCIENCE
7.3.1 INDICAL BIOSCIENCE Company Information
7.3.2 INDICAL BIOSCIENCE Business Overview
7.3.3 INDICAL BIOSCIENCE Biomolecule Software Revenue and Gross Margin (2021-2026)
7.3.4 INDICAL BIOSCIENCE Biomolecule Software Product Portfolio
7.3.5 INDICAL BIOSCIENCE Recent Developments
7.4 lexogen
7.4.1 lexogen Company Information
7.4.2 lexogen Business Overview
7.4.3 lexogen Biomolecule Software Revenue and Gross Margin (2021-2026)
7.4.4 lexogen Biomolecule Software Product Portfolio
7.4.5 lexogen Recent Developments
7.5 Repligen
7.5.1 Repligen Company Information
7.5.2 Repligen Business Overview
7.5.3 Repligen Biomolecule Software Revenue and Gross Margin (2021-2026)
7.5.4 Repligen Biomolecule Software Product Portfolio
7.5.5 Repligen Recent Developments
7.6 SCC SOFT COMPUTER
7.6.1 SCC SOFT COMPUTER Company Information
7.6.2 SCC SOFT COMPUTER Business Overview
7.6.3 SCC SOFT COMPUTER Biomolecule Software Revenue and Gross Margin (2021-2026)
7.6.4 SCC SOFT COMPUTER Biomolecule Software Product Portfolio
7.6.5 SCC SOFT COMPUTER Recent Developments
7.7 Oxford Instruments
7.7.1 Oxford Instruments Company Information
7.7.2 Oxford Instruments Business Overview
7.7.3 Oxford Instruments Biomolecule Software Revenue and Gross Margin (2021-2026)
7.7.4 Oxford Instruments Biomolecule Software Product Portfolio
7.7.5 Oxford Instruments Recent Developments
7.8 Partek, Inc.
7.8.1 Partek, Inc. Company Information
7.8.2 Partek, Inc. Business Overview
7.8.3 Partek, Inc. Biomolecule Software Revenue and Gross Margin (2021-2026)
7.8.4 Partek, Inc. Biomolecule Software Product Portfolio
7.8.5 Partek, Inc. Recent Developments
7.9 Stilla Technologies
7.9.1 Stilla Technologies Company Information
7.9.2 Stilla Technologies Business Overview
7.9.3 Stilla Technologies Biomolecule Software Revenue and Gross Margin (2021-2026)
7.9.4 Stilla Technologies Biomolecule Software Product Portfolio
7.9.5 Stilla Technologies Recent Developments
7.10 Vela Diagnostics
7.10.1 Vela Diagnostics Company Information
7.10.2 Vela Diagnostics Business Overview
7.10.3 Vela Diagnostics Biomolecule Software Revenue and Gross Margin (2021-2026)
7.10.4 Vela Diagnostics Biomolecule Software Product Portfolio
7.10.5 Vela Diagnostics Recent Developments
7.11 Vittoriobasurto
7.11.1 Vittoriobasurto Company Information
7.11.2 Vittoriobasurto Business Overview
7.11.3 Vittoriobasurto Biomolecule Software Revenue and Gross Margin (2021-2026)
7.11.4 Vittoriobasurto Biomolecule Software Product Portfolio
7.11.5 Vittoriobasurto Recent Developments
7.12 SCIEX
7.12.1 SCIEX Company Information
7.12.2 SCIEX Business Overview
7.12.3 SCIEX Biomolecule Software Revenue and Gross Margin (2021-2026)
7.12.4 SCIEX Biomolecule Software Product Portfolio
7.12.5 SCIEX Recent Developments
7.13 SoftGenetics, LLC.
7.13.1 SoftGenetics, LLC. Company Information
7.13.2 SoftGenetics, LLC. Business Overview
7.13.3 SoftGenetics, LLC. Biomolecule Software Revenue and Gross Margin (2021-2026)
7.13.4 SoftGenetics, LLC. Biomolecule Software Product Portfolio
7.13.5 SoftGenetics, LLC. Recent Developments
7.14 Benchling
7.14.1 Benchling Company Information
7.14.2 Benchling Business Overview
7.14.3 Benchling Biomolecule Software Revenue and Gross Margin (2021-2026)
7.14.4 Benchling Biomolecule Software Product Portfolio
7.14.5 Benchling Recent Developments
7.15 BioSistemika
7.15.1 BioSistemika Company Information
7.15.2 BioSistemika Business Overview
7.15.3 BioSistemika Biomolecule Software Revenue and Gross Margin (2021-2026)
7.15.4 BioSistemika Biomolecule Software Product Portfolio
7.15.5 BioSistemika Recent Developments
7.16 CapitalBio Technology
7.16.1 CapitalBio Technology Company Information
7.16.2 CapitalBio Technology Business Overview
7.16.3 CapitalBio Technology Biomolecule Software Revenue and Gross Margin (2021-2026)
7.16.4 CapitalBio Technology Biomolecule Software Product Portfolio
7.16.5 CapitalBio Technology Recent Developments
7.17 cytena GmbH
7.17.1 cytena GmbH Company Information
7.17.2 cytena GmbH Business Overview
7.17.3 cytena GmbH Biomolecule Software Revenue and Gross Margin (2021-2026)
7.17.4 cytena GmbH Biomolecule Software Product Portfolio
7.17.5 cytena GmbH Recent Developments
7.18 Eppendorf SE
7.18.1 Eppendorf SE Company Information
7.18.2 Eppendorf SE Business Overview
7.18.3 Eppendorf SE Biomolecule Software Revenue and Gross Margin (2021-2026)
7.18.4 Eppendorf SE Biomolecule Software Product Portfolio
7.18.5 Eppendorf SE Recent Developments
7.19 GenomSys
7.19.1 GenomSys Company Information
7.19.2 GenomSys Business Overview
7.19.3 GenomSys Biomolecule Software Revenue and Gross Margin (2021-2026)
7.19.4 GenomSys Biomolecule Software Product Portfolio
7.19.5 GenomSys Recent Developments
7.20 Mission Bio
7.20.1 Mission Bio Company Information
7.20.2 Mission Bio Business Overview
7.20.3 Mission Bio Biomolecule Software Revenue and Gross Margin (2021-2026)
7.20.4 Mission Bio Biomolecule Software Product Portfolio
7.20.5 Mission Bio Recent Developments
7.21 Multid Analyses AB
7.21.1 Multid Analyses AB Company Information
7.21.2 Multid Analyses AB Business Overview
7.21.3 Multid Analyses AB Biomolecule Software Revenue and Gross Margin (2021-2026)
7.21.4 Multid Analyses AB Biomolecule Software Product Portfolio
7.21.5 Multid Analyses AB Recent Developments
7.22 PhenoSystems SA
7.22.1 PhenoSystems SA Company Information
7.22.2 PhenoSystems SA Business Overview
7.22.3 PhenoSystems SA Biomolecule Software Revenue and Gross Margin (2021-2026)
7.22.4 PhenoSystems SA Biomolecule Software Product Portfolio
7.22.5 PhenoSystems SA Recent Developments
7.23 Progenie Molecular
7.23.1 Progenie Molecular Company Information
7.23.2 Progenie Molecular Business Overview
7.23.3 Progenie Molecular Biomolecule Software Revenue and Gross Margin (2021-2026)
7.23.4 Progenie Molecular Biomolecule Software Product Portfolio
7.23.5 Progenie Molecular Recent Developments
8 North America
8.1 North America Biomolecule Software Revenue (2021-2032)
8.2 North America Biomolecule Software Revenue by Type (2021-2032)
8.2.1 North America Biomolecule Software Revenue by Type (2021-2026)
8.2.2 North America Biomolecule Software Revenue by Type (2027-2032)
8.3 North America Biomolecule Software Revenue Share by Type (2021-2032)
8.4 North America Biomolecule Software Revenue by Application (2021-2032)
8.4.1 North America Biomolecule Software Revenue by Application (2021-2026)
8.4.2 North America Biomolecule Software Revenue by Application (2027-2032)
8.5 North America Biomolecule Software Revenue Share by Application (2021-2032)
8.6 North America Biomolecule Software Revenue by Country
8.6.1 North America Biomolecule Software Revenue by Country (2021 VS 2025 VS 2032)
8.6.2 North America Biomolecule Software Revenue by Country (2021-2026)
8.6.3 North America Biomolecule Software Revenue by Country (2027-2032)
8.6.4 United States
8.6.5 Canada
8.6.6 Mexico
9 Europe
9.1 Europe Biomolecule Software Revenue (2021-2032)
9.2 Europe Biomolecule Software Revenue by Type (2021-2032)
9.2.1 Europe Biomolecule Software Revenue by Type (2021-2026)
9.2.2 Europe Biomolecule Software Revenue by Type (2027-2032)
9.3 Europe Biomolecule Software Revenue Share by Type (2021-2032)
9.4 Europe Biomolecule Software Revenue by Application (2021-2032)
9.4.1 Europe Biomolecule Software Revenue by Application (2021-2026)
9.4.2 Europe Biomolecule Software Revenue by Application (2027-2032)
9.5 Europe Biomolecule Software Revenue Share by Application (2021-2032)
9.6 Europe Biomolecule Software Revenue by Country
9.6.1 Europe Biomolecule Software Revenue by Country (2021 VS 2025 VS 2032)
9.6.2 Europe Biomolecule Software Revenue by Country (2021-2026)
9.6.3 Europe Biomolecule Software Revenue by Country (2027-2032)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
9.6.9 Spain
9.6.10 Netherlands
9.6.11 Switzerland
9.6.12 Sweden
9.6.13 Poland
10 China
10.1 China Biomolecule Software Revenue (2021-2032)
10.2 China Biomolecule Software Revenue by Type (2021-2032)
10.2.1 China Biomolecule Software Revenue by Type (2021-2026)
10.2.2 China Biomolecule Software Revenue by Type (2027-2032)
10.3 China Biomolecule Software Revenue Share by Type (2021-2032)
10.4 China Biomolecule Software Revenue by Application (2021-2032)
10.4.1 China Biomolecule Software Revenue by Application (2021-2026)
10.4.2 China Biomolecule Software Revenue by Application (2027-2032)
10.5 China Biomolecule Software Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
11.1 Asia Biomolecule Software Revenue (2021-2032)
11.2 Asia Biomolecule Software Revenue by Type (2021-2032)
11.2.1 Asia Biomolecule Software Revenue by Type (2021-2026)
11.2.2 Asia Biomolecule Software Revenue by Type (2027-2032)
11.3 Asia Biomolecule Software Revenue Share by Type (2021-2032)
11.4 Asia Biomolecule Software Revenue by Application (2021-2032)
11.4.1 Asia Biomolecule Software Revenue by Application (2021-2026)
11.4.2 Asia Biomolecule Software Revenue by Application (2027-2032)
11.5 Asia Biomolecule Software Revenue Share by Application (2021-2032)
11.6 Asia Biomolecule Software Revenue by Country
11.6.1 Asia Biomolecule Software Revenue by Country (2021 VS 2025 VS 2032)
11.6.2 Asia Biomolecule Software Revenue by Country (2021-2026)
11.6.3 Asia Biomolecule Software Revenue by Country (2027-2032)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 Taiwan
11.6.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Biomolecule Software Revenue (2021-2032)
12.2 SAMEA Biomolecule Software Revenue by Type (2021-2032)
12.2.1 SAMEA Biomolecule Software Revenue by Type (2021-2026)
12.2.2 SAMEA Biomolecule Software Revenue by Type (2027-2032)
12.3 SAMEA Biomolecule Software Revenue Share by Type (2021-2032)
12.4 SAMEA Biomolecule Software Revenue by Application (2021-2032)
12.4.1 SAMEA Biomolecule Software Revenue by Application (2021-2026)
12.4.2 SAMEA Biomolecule Software Revenue by Application (2027-2032)
12.5 SAMEA Biomolecule Software Revenue Share by Application (2021-2032)
12.6 SAMEA Biomolecule Software Revenue by Country
12.6.1 SAMEA Biomolecule Software Revenue by Country (2021 VS 2025 VS 2032)
12.6.2 SAMEA Biomolecule Software Revenue by Country (2021-2026)
12.6.3 SAMEA Biomolecule Software Revenue by Country (2027-2032)
12.6.4 Brazil
12.6.5 Argentina
12.6.6 Chile
12.6.7 Colombia
12.6.8 Peru
12.6.9 Saudi Arabia
12.6.10 Israel
12.6.11 UAE
12.6.12 Turkey
12.6.13 Iran
12.6.14 Egypt
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.